STAT+: Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion
LONDON — The booming obesity market is attracting another player, as pharma giant Roche said…
Category: obesity
STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial
Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after…
Frontline: Phototherapy for Alzheimer’s Treatment; Timing of Exercise and Weight Loss; Knee Replacement Surgery
Phototherapy Demonstrates Promise for Alzheimer’s Treatment A new study has demonstrated promising results using photobiomodulation…
STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle
Have you ever seen a mouse with a set of muscles more appropriate for a…
Type 2 diabetes prevention programs can work at large scale, study finds
LONDON — Clinical trials have shown that lifestyle programs — which include diet, exercise, and…
AMA urges coverage of obesity treatments as payers balk at costs
WASHINGTON – The American Medical Association called on insurance companies, employers, and government programs to…
STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug
PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a…
STAT+: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation
PHILADELPHIA – Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster…
Wegovy cuts risk of heart attacks in milestone cardiovascular trial
PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in…
STAT+: EU regulator recommends expanding diabetes drug Mounjaro’s approval to include obesity
LONDON — Two days after similar decisions in the U.S. and U.K., regulators in Europe…
Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion
What’s a radiopharmaceutical? What does it mean to be Zepbound? And who’s to blame for…
Avoiding Insulin Resistance
Left unchecked, the common condition known as insulin resistance can lead to prediabetes and type…
Injectable Semaglutide Formulation Makes Compliance with Healthy Diet Easier
You’ve probably heard about semaglutide; it is branded as Ozempic and Rybelsus for diabetes management…
What’s the Skinny on Weight-Loss Meds?
Obesity is a serious and common health issue that has historically been misunderstood. In fact,…
Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Massachusetts biotechs seek to piggyback on weight loss drug boom
The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and…
STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro
As demand for weight-loss treatments intensifies, Eli Lilly has filed a complaint with the U.S….
Lotte Knudsen, who pushed Novo Nordisk into the Ozempic era, wins STAT Innovation award
Back in the 1990s, scientist Lotte Bjerre Knudsen was tasked with revitalizing a floundering program…
STAT+: Why doesn’t everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues
DALLAS — Treatments like Ozempic, Wegovy, and Mounjaro have been hailed for showing 15% to…
STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic
There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for…
STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies
DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and…
STAT+: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse
Lotte Bjerre Knudsen was still getting used to all the empty benches in her lab…
Studies highlight risks of excluding people with obesity from drug trials
People with obesity often go underrepresented in drug development trials, a critical gap that researchers…
Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs
When is a billion-dollar deal a bad omen? Has Wall Street gone overboard on Ozempic?…
Opinion: The Wegovy shortage is part of a much bigger problem with weight loss drugs
After physically debilitating cancer treatment, Laurie Brunner encountered another medical hurdle: She had developed lymphedema…
GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?
Next week, 50 medical experts from the Karolinska Institutet in Stockholm will meet to award…
Listen: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech’s slump
When is negative data positive enough? Who gets credit for scientific breakthroughs? And wasn’t biotech…
STAT+: What will Novo’s VC do with its influx of cash? Don’t expect obesity investments
The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the…
STAT+: The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she’s been edged out of the story
On a mild May day in 1993, about 60 scientists and doctors gathered on a…
Newsbites: Body mass index data; healthy eating and sleep; MIND diet for cognitive health
New Data on Body Mass Index (BMI) Body Mass Index (BMI) is a ratio of…
Take Steps to Limit Vision Loss from Age-Related Macular Degeneration
It’s not unusual to experience vision changes as you age, but some changes are normal…
STAT+: New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro
The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to…
STAT+: Here are the dozens of weight loss drugs in development to catch a booming market
The blazing success of weight loss drugs like Wegovy and Mounjaro has electrified the pursuit…
.jpg)
Obesity-related cardiovascular deaths tripled in the last two decades, new study finds
Heart disease is killing fewer Americans overall, however, cardiovascular deaths where obesity was listed as…
Biotech execs vie for a share of obesity drug boom: ‘It’s the early innings’
Pharma giants Novo Nordisk and Eli Lilly might’ve led the way into a new era…
Research Roundup September 2023
• Diet and Dementia Risk. Adherence to the MIND (Mediterranean-DASH) diet is linked with lower…
What do new weight loss drugs mean for the future of bariatric surgery?
Over the past year, weight loss drugs have captured the public’s imagination but also raised…
Good News About Colon Screenings
Most people don’t give their colon a second thought until it’s time for a colonoscopy….
STAT+: Weight loss drug Wegovy improves function in people with common type of heart failure
Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of…
STAT+: What past blockbusters can tell us about future of Wegovy and other weight loss medicines
The news that the weight loss drug Wegovy reduced the risk of heart attacks and…
STAT+: Obesity specialists are scarce. Here’s how that’s starting to change
Treatment of obesity has never been more prominent, with the advent of medications like Ozempic…
STAT+: As the obesity drug market grows, digital health companies juggle patients and payers
To much of the public, the promise of telehealth is all about convenience — get…
STAT+: What to know about concerns raised about compounded versions of Novo Nordisk’s Wegovy
As demand for Ozempic and Wegovy surges, a little noticed warning about the medicines was…
Listen: Your guide to Wegovy’s blockbuster heart study
Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And…
STAT+: Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach
Fresh off of the news that its drug Wegovy may not just help people lose…
STAT+: Telehealth companies are driving a large share of weight loss drug prescriptions, claims data suggest
As a new class of obesity medications has soared in popularity, so have the online…
STAT+: Novo Nordisk celebrates landmark Wegovy study, even as supply issues persist
The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives…
STAT+: Wegovy’s successful heart trial raises a vital question about weight loss
A landmark study that found the blockbuster obesity drug Wegovy reduces the chance of heart…
STAT+: Novo’s obesity drug Wegovy lowers cardiovascular risk by 20%, landmark trial finds
Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in…
STAT+: Alarmed by popularity of Ozempic and Wegovy, insurers wage multi-front battle
Patients are bracing for “D-Day,” the date their insurance companies will stop covering the drugs….